Eucrates Biomedical Acquisition Corp. Warrant
EUCRW
EUCRW was delisted on the 26th of April, 2023.
24 hedge funds and large institutions have $691K invested in Eucrates Biomedical Acquisition Corp. Warrant in 2022 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
26% more funds holding
Funds holding: 19 → 24 (+5)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
71% less capital invested
Capital invested by funds: $2.4M → $691K (-$1.71M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$67.3K |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$10.7K |
| 3 |
WRBC
W.R. Berkley Corp
Greenwich,
Connecticut
|
+$10.7K |
| 4 |
OMC
Old Mission Capital
Chicago,
Illinois
|
+$4.39K |
| 5 |
CAC
Cowen and Company
New York
|
+$3.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$27K |
| 2 |
GCL
Glazer Capital LLC
New York
|
-$2.03K |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$952 |
EUCRW Hedge Fund Activity: Q1 2022 in Review
24 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) for Q1 2022, worth a combined $691K — down 71% from $2.4M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new EUCRW positions and 1 closed out — a net gain of 5 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $67.3K. The largest seller was EcoR1 Capital, exiting entirely with an estimated $27K sold.
- 24 institutional investors held Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) as of Q1 2022, up from 19 in Q4 2021.
- Funds reported $691K of Eucrates Biomedical Acquisition Corp. Warrant stock for Q1 2022, down 71% quarter-over-quarter.
- 6 funds opened new Eucrates Biomedical Acquisition Corp. Warrant positions in Q1 2022 and 1 closed out, a net change of +5 holders.
- The largest Eucrates Biomedical Acquisition Corp. Warrant buyer in Q1 2022 was Goldman Sachs, an estimated $67.3K added.
- The largest Eucrates Biomedical Acquisition Corp. Warrant seller in Q1 2022 was EcoR1 Capital, an estimated $27K sold.
Based on aggregated 13F filings for Q1 2022.